Newcells Biotech Limited

Newcells Biotech Limited, based in the UK, is dedicated to developing advanced in vitro tissue models that replicate human physiology, primarily focused on enhancing drug discovery and clinical translation. Newcells Biotech Limited specializes in creating innovative in vitro tissue models to support pharmaceutical research. Founded in 2014 and headquartered in Newcastle upon Tyne, UK, the company has successfully completed five funding deals. Its most recent deal occurred in November 2024, when it raised GBP 1.

2 million from Mercia Asset Management, North East Fund, and Northstar Ventures, bringing the total amount raised to GBP 1. 2 million. The firm is led by Professor Armstrong as the founder and Mike Nicholds as CEO. Newcells Biotech specializes in developing advanced in vitro tissue models that closely mimic human physiology, aimed at improving drug discovery and clinical translation.

Their core offerings include retinal organoids and pigmented epithelium models for studying retinopathies, as well as proximal tubule models for renal toxicity evaluations. These products provide predictive data for drug efficacy and safety, targeting applications such as disease modeling, drug interactions, and therapeutic assessments. The company primarily serves pharmaceutical and biotechnology companies, research institutions, and academic organizations across global markets, including Europe, North America, and Asia. By providing bespoke study designs and comprehensive assay services, Newcells Biotech addresses critical needs in pre-clinical drug development.

The revenue model for Newcells Biotech is structured around service contracts and partnerships with clients in the pharmaceutical and biotechnology sectors. The company engages in B2B transactions, where clients commission studies utilizing Newcells’ in vitro models for drug development purposes. Their offerings include tailored efficacy and safety testing services, alongside products that facilitate in-house testing. Revenue is generated through these contractual agreements, comprising both one-time fees for specific studies and ongoing partnerships for continuous research support.

While specific pricing details for individual services are proprietary, the company’s established track record and recognized expertise position it favorably within its market sector. In November 2024, Newcells Biotech Limited raised GBP 1. 2 million in venture funding, which will be utilized to build its customer base and develop partnerships with companies offering complementary products. The company plans to expand its offerings with new products designed to enhance their in vitro models.

Additionally, Newcells aims to penetrate new markets, specifically targeting regions in Europe and North America by the end of 2025.